Browse > Article

Modulation of Pituitary Somatostatin Receptor Subtype (sst1-5) mRNA Levels by Growth Hormone (GH)-Releasing Hormone in Purified Somatotropes  

Park, Seung-Joon (Department of Pharmacology, Kyunghee University School of Medicine)
Park, Hee-Soon (Department of Pharmacology, Kyunghee University School of Medicine)
Lee, Mi-Na (Department of Pharmacology, Kyunghee University School of Medicine)
Sohn, Sook-Jin (Department of Pharmacology, Kyunghee University School of Medicine)
Kim, Eun-Hee (Department of Pharmacology, Kyunghee University School of Medicine)
Jung, Jee-Chang (Department of Pharmacology, Kyunghee University School of Medicine)
Frohman, Lawrence A. (Department of Medicine, Section of Endocrinology and Metabolism, University of Illinois at Chicago)
Kineman, Rhonda D. (Department of Medicine, Section of Endocrinology and Metabolism, University of Illinois at Chicago)
Publication Information
The Korean Journal of Physiology and Pharmacology / v.7, no.2, 2003 , pp. 79-84 More about this Journal
Abstract
We have previously reported that expression of the somatostatin receptor subtypes, sst1-5, is differentially regulated by growth hormone (GH)-releasing hormone (GHRH) and forskolin (FSK), in vitro. GHRH binds to membrane receptors selectively located on pituitary somatotropes, activates adenylyl cyclase (AC) and increases sst1 and sst2 and decreases sst5 mRNA levels, without significantly altering the expression of sst3 and sst4. In contrast FSK directly activates AC in all pituitary cell types and increases sst1 and sst2 mRNA levels and decreases sst3, sst4 and sst5 expression. Two explanations could account for these differential effects: 1) GHRH inhibits sst3 and sst4 expression in somatotropes, but this inhibitory effect is masked by expression of these receptors in unresponsive pituitary cell types, and 2) FSK inhibits sst3 and sst4 expression levels in pituitary cell types other than somatotropes. To differentiate between these two possibilities, somatotropes were sequentially labeled with monkey anti-rat GH antiserum, biotinylated goat anti-human IgG, and streptavidin-PE and subsequently purified by fluorescent-activated cell sorting (FACS). The resultant cell population consisted of 95% somatotropes, as determined by GH immunohistochemistry using a primary GH antiserum different from that used for FACS sorting. Purified somatotropes were cultured for 3 days and treated for 4 h with vehicle, GHRH (10 nM) or FSK ($10{\mu}M$). Total RNA was isolated by column extraction and specific receptor mRNA levels were determined by semi-quantitative multiplex RT-PCR. Under basal conditions, the relative expression levels of the various somatostatin receptor subtypes were sst2>sst5>sst3=sst1> sst4. GHRH treatment increased sst1 and sst2 mRNA levels and decreased sst3, sst4 and sst5 mRNA levels in purified somatotropes, comparable to the effects of FSK on purified somatotropes and mixed pituitary cell cultures. Taken together, these results demonstrate that GHRH acutely modulates the expression of all somatostatin receptor subtypes within GH-producing cells and its actions are likely mediated by activation of AC.
Keywords
GHRH; Forskolin; Somatostatin receptor; Somatotrope; cAMP; Adenylyl cyclase;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Lopes MBS, Gaylinn BD, Thorner MO, Stoler MH. Growth hormone-releasing hormone receptor mRNA in acromegalic pituitary tumors. Am J Pathol 150: 1885-1891, 1997
2 Mezey E, Hunyady B, Mitra S, Hayes E, Liu Q, Schaeffer J, Schonbrunn A. Cell specific expression of the sst2A and sst5 somatostatin receptors in the rat anterior pituitary. Endocrinology 139: 414-419, 1998   DOI   ScienceOn
3 Morel G, Gallego R, Boulanger L, Pintos E, Garcia-Caballero T, Gaudreau P. Restricted presence of the growth hormonereleasing hormone receptor to somatotropes in rat and human pituitaries. Neuroendocrinology 70: 128-136, 1999   DOI   ScienceOn
4 Oka H, Kameya T, Sato Y, Naritaka H, Kawano N. Significance of growth hormone-releasing hormone receptor mRNA in non-neoplastic pituitary and pituitary adenomas: a study by RT-PCR and in situ hybridization. J Neurooncol 41: 197-204, 1999   DOI   ScienceOn
5 Rohrer SP, Hayes E, Berk SC, Hutchins SM, Shen D-M, Xiong Y, Parma R, Foor P, Mitra SW, Degrado SJ, Shu M, Klopp JM, Cai SJ, Blake A, Chan WW, Pasternak A, Yang L, Patchett A, Smith RG, Chapman KT, Schaeffer JM. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 282: 737-740, 1998   DOI   PUBMED   ScienceOn
6 Wynick D, Venetikou MS, Critchley R, Burrin JM, Bloom SR. Flow cytometric analysis of functional anterior pituitary cells from female rats. J Endocrinol 126: 261-268, 1990b   DOI   ScienceOn
7 Kineman RD, Aleppo G, Frohman LA. The tyrosine hydroxy lase-human growth hormone (GH) transgenic mouse as a model of hypothalamic GH deficiency: growth retardation is the result of a selective reduction in somatotrope numbers despite normal somatotrope function. Endocrinology 137: 4630-4636, 1996   DOI   PUBMED
8 Panetta R, Patel YC. Expression of mRNA for all 5 human somatostatin receptor (hSSTR1-5) in pituitary tumors. Life Sci 56: 333-342, 1995   DOI   PUBMED   ScienceOn
9 Kumar U, Laird D, Srikant CB, Escher E, Patel YC. Expression of the five somatostatin receptor (SSTR1-5) subtypes in rat pituitary somatotropes: quantitative analysis by double-label immunoflourescence confocal microscopy. Endocrinology 138: 4473-4476, 1997   DOI   PUBMED   ScienceOn
10 Greenman Y, Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79: 724-729, 1994b   DOI   ScienceOn
11 Greenman Y, Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 78: 398-403, 1994a   DOI   ScienceOn
12 Smith RG, Van Der Ploeg HT, Howard AD, Feighner SD, Cheng K, Hickey GJ, Wyvratt MJ. Peptidomimetic regulation of growth hormone secretion. Endocr Rev 18: 621-645, 1997   DOI   ScienceOn
13 Reisine T. Somatostatin. Cell Mol Neurobiol 15: 597-614, 1995   DOI   PUBMED   ScienceOn
14 Aleppo G, Moskal SFI, DeGrandis PA, Kineman RD, Frohman LA. Homologous down-regulation of growth hormone-releasing hormone receptor mRNA levels. Endocrinology 138: 1058-1065, 1997   DOI   ScienceOn
15 Wynick D, Critchley R, Venetikou MS, Burrin JM, Bloom SR. Purification of functional lactotrophs and somatotrophs from female rats using fluorescence-activated cell sorting. J Endocrinol 126: 269-274, 1990a   DOI   ScienceOn
16 Day R, Dong W, Panetta R, Kracier J, Greenwood MT, Patel YC. Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double labeling in situ hybridization analysis. Endocrinology 136: 5232-5235, 1995   DOI   ScienceOn
17 Park S, Kamegai J, Johnson TA, Frohman LA, Kineman RD. Modulation of pituitary somatostatin receptor subtype (sst1-5) messenger ribonucleic acid levels by changes in the growth hormone axis. Endocrinology 141: 3556-3530, 2000   DOI   PUBMED   ScienceOn
18 Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Margan B, Coy DH, Culler MD, Melmed S. Somatostatin receptor subtype specificity in human fetal pituitary cultures. J Clin Invest 99: 789-798, 1997a   DOI   ScienceOn
19 O'Carroll AM, Krempels K. Widespread distribution of somatostatin receptor messenger ribonucleic acids in rat pituitary. Endcorinology 136: 5224-5227, 1995   DOI   ScienceOn
20 Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas: novel potential therapy for functioning pituitary tumors. J Clin Invest 100: 2386-2392, 1997b   DOI   ScienceOn
21 Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 20: 157-198, 1999   DOI   PUBMED   ScienceOn